1 day Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Global Markets The Wall Street Journal
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved patient population.
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved patient population.